Skip to main content
Y

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,854 across all filing types
Latest filing 2026-04-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
2025年度独立董事履职报告（王小岩）
Governance Information Classification · 1% confidence The document is the 2025 Independent Director’s Annual Performance Report by a board member (“独立董事履职报告”), detailing his attendance at board and committee meetings, compliance with governance rules, communication with auditors and shareholders, and self-evaluation. It is a substantive governance disclosure rather than a mere announcement or financial report. This aligns with Governance Information (CGR), which covers company governance practices and board-related reports.
2026-04-22 Chinese
益丰药房2026年第一季度报告
Interim / Quarterly Report Classification · 1% confidence The document is titled '2026年第一季度报告' (2026 First Quarter Report) for Yifeng Pharmacy Chain Co., Ltd. It contains comprehensive financial statements, including the balance sheet, income statement, and cash flow statement for the first quarter of 2026, along with management's discussion of financial data and shareholder information. It is a full quarterly financial report, not an announcement or a summary, and therefore fits the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-04-22 Chinese
益丰药房2025年社会、环境与公司治理报告摘要
Environmental & Social Information Classification · 1% confidence The document is the “2025年度环境、社会和公司治理报告摘要” (2025 Environmental, Social and Governance Report Summary) for Yifeng Pharmacy. It contains ESG governance structure, stakeholder communication, materiality assessment, and sustainability data. This aligns exactly with an Environmental & Social Information report (Code: SR). It is not merely an announcement or a full annual report but is a specialized ESG summary, fitting the SR category.
2026-04-22 Chinese
董事会议事规则（2026年4月修订）
Governance Information Classification · 1% confidence The document is not a meeting notice, minutes, or financial report but a detailed set of internal governance rules outlining the board’s structure, duties, meeting procedures, and decision-making processes. It defines the company’s board governance framework and bylaws rather than announcing any specific transaction, financial results, or management change. This corresponds to Governance Information (CGR).
2026-04-22 Chinese
董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 1% confidence The document is a special report issued by the board assessing the independence of the company’s independent directors, referencing regulatory rules on independent director governance. This is not a full annual or interim report, not an earnings release or voting result, but rather a governance compliance report. It therefore fits the Governance Information category (CGR).
2026-04-22 Chinese
2025年度会计师事务所履职情况评估报告
Regulatory Filings Classification · 1% confidence The document is a detailed evaluation report by the company’s audit committee on the performance and independence of its appointed external auditor for 2025. It is not an Annual Report or the audited financial statements themselves, nor is it an earnings release, dividend notice, M&A announcement, or management discussion. It is also not a simple notice announcing publication of another report. There is no specific slot in our taxonomy for an auditor performance evaluation, so this falls under the fallback category “Regulatory Filings (RNS).”
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.